<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story</h2>
    <div class="badge">2025-09-08T14:15:51+00:00</div>
    <ul>
      <li>Uncover how Chugai Pharmaceutical&#x27;s forecasts yield a ¥8082 fair value, a 21% upside to its current price.</li>
<li>This projection is based on a 4.9% annual revenue growth rate and represents a ¥121.5 billion increase in earnings from the current ¥395.4 billion.</li>
<li>Read the full narrative on Chugai Pharmaceutical (it&#x27;s free!) Chugai Pharmaceutical&#x27;s outlook forecasts ¥1,381.4 billion in revenue and ¥516.9 billion in earnings by 2028.</li>
<li>How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story - On August 26, 2025, Chugai Pharmaceutical reported that Eli Lilly announced positive topline Phase 3 result</li>
<li>Exploring Other Perspectives Two unique fair value estimates from the Simply Wall St Community range from ¥8,082 to ¥8,689 per share.</li>
<li>These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer&#x27;s.</li>
<li>The end of cancer?</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story\n• Uncover how Chugai Pharmaceutical&#x27;s forecasts yield a ¥8082 fair value, a 21% upside to its current price.\n• This projection is based on a 4.9% annual revenue growth rate and represents a ¥121.5 billion increase in earnings from the current ¥395.4 billion.\n• Read the full narrative on Chugai Pharmaceutical (it&#x27;s free!) Chugai Pharmaceutical&#x27;s outlook forecasts ¥1,381.4 billion in revenue and ¥516.9 billion in earnings by 2028.\n• How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story - On August 26, 2025, Chugai Pharmaceutical reported that Eli Lilly announced positive topline Phase 3 result\n• Exploring Other Perspectives Two unique fair value estimates from the Simply Wall St Community range from ¥8,082 to ¥8,689 per share.\n• These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer&#x27;s.\n• The end of cancer?" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/positive-phase-3-results-orforglipron-141551068.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>